ArticleNeuropsychiatric disease and treatment2018
Elevated peripheral blood glutamate levels in major depressive disorder.
Article in Neuropsychiatric disease and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder.Molecular psychiatry · 2021Pooled it
- Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders.Translational psychiatry · 2020Pooled it
- Associations between serum amino acids and genetic liability to depression in the LURIC cohort.BMC psychiatry · 2026Article
- Measurement of Serum Parameters Attributes the Therapeutic Effects of Music Therapy to Augmented Stress-Coping Ability and Diminished Systemic Inflammation.Depression and anxiety · 2026Article
- Beyond Protein Building Blocks: A Review of Biological Roles and Therapeutic Potential of Free Amino Acids.International journal of molecular sciences · 2025Review
- Mechanistic intersections between migraine and major depressive disorder.The journal of headache and pain · 2025Review
- Alterations of serum metabolic profile in major depressive disorder: A case-control study in the Chinese population.World journal of psychiatry · 2025Article
- Altered synaptic homeostasis: a key factor in the pathophysiology of depression.Cell & bioscience · 2025Review
- Neuroprotection of paeoniflorin as antidepressant candidate.BioMedicine · 2025Article
- Aberrant glutamatergic systems underlying impulsive behaviors: Insights from clinical and preclinical research.Progress in neuro-psychopharmacology & biological psychiatry · 2024Review
- Review
- Plasma amino acids in major depressive disorder: between pathology to pharmacology.EXCLI journal · 2024Review
- Review
- The Importance of α-Klotho in Depression and Cognitive Impairment and Its Connection to Glutamate Neurotransmission-An Up-to-Date Review.International journal of molecular sciences · 2023Review
- Circulating metabolites modulated by diet are associated with depression.Molecular psychiatry · 2023Article
- The Utility of Amino Acid Metabolites in the Diagnosis of Major Depressive Disorder and Correlations with Depression Severity.International journal of molecular sciences · 2023Article
- Metabolomics in aging research: aging markers from organs.Frontiers in cell and developmental biology · 2023Review
- Article
- Gut Microbiota Metabolites in Major Depressive Disorder-Deep Insights into Their Pathophysiological Role and Potential Translational Applications.Metabolites · 2022Review
- Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization.Frontiers in psychiatry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThere is growing evidence that glutamatergic signaling may be involved in major depressive disorder (MDD). In regard to peripheral blood glutamate changes in MDD, inconsistent findings have been reported. The purpose of the present study was to evaluate whether blood glutamate levels differed between MDD patients and control participants. MATERIALS AND
methodsWe conducted a systematic review and meta-analysis of 12 association studies between blood glutamate levels and MDD in a total of 529 MDD patients and 590 controls. Subsequently, we conducted subgroup analyses and a meta-regression analysis to examine the sources of potential heterogeneity.
resultsA random effects model showed that blood glutamate levels were significantly higher in MDD patients than in controls (standardized mean difference=0.54, 95% CI=0.27-0.82,
conclusionOur findings suggest that altered glutamate levels may be implicated in MDD, which provides further evidence of glutamatergic dysfunction in MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.